Stock GE91 GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genmab A/S Börse Stuttgart

Equities

GE91

US3723032062

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 17:47:57 26/06/2024 BST 		5-day change 1st Jan Change
23.9 EUR -0.42% Intraday chart for Genmab A/S +3.42% -15.97%
06-10 Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
06-04 Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 96,408 161,105 172,063 192,229 140,770 114,468 - -
Enterprise Value (EV) 1 85,618 145,026 152,725 169,905 112,635 88,584 82,263 75,601
P/E ratio 43.5 x 34.1 x 57.8 x 35.2 x 32.6 x 26.5 x 19.3 x 14.6 x
Yield - - - - - - - -
Capitalization / Revenue 18 x 15.9 x 20.3 x 13.2 x 8.54 x 5.78 x 4.85 x 4.04 x
EV / Revenue 16 x 14.3 x 18 x 11.6 x 6.84 x 4.47 x 3.48 x 2.67 x
EV / EBITDA 30.8 x 22.1 x 46.8 x 25.3 x 20.1 x 14 x 9.9 x 6.92 x
EV / FCF 68.7 x 23.7 x 77.3 x 47.3 x 16.1 x 32.4 x 13.8 x 8.82 x
FCF Yield 1.46% 4.22% 1.29% 2.12% 6.23% 3.08% 7.23% 11.3%
Price to Book 6.85 x 8.5 x 7.82 x 7.07 x 4.5 x 3.37 x 2.74 x 2.29 x
Nbr of stocks (in thousands) 65,075 65,410 65,423 65,362 65,322 63,629 - -
Reference price 2 1,482 2,463 2,630 2,941 2,155 1,799 1,799 1,799
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,366 10,111 8,482 14,595 16,474 19,803 23,614 28,307
EBITDA 1 2,777 6,572 3,266 6,719 5,616 6,324 8,308 10,930
EBIT 1 2,638 6,313 3,018 6,357 5,321 5,929 7,844 10,464
Operating Margin 49.16% 62.44% 35.58% 43.56% 32.3% 29.94% 33.22% 36.96%
Earnings before Tax (EBT) 1 2,859 5,904 3,983 7,035 5,637 5,853 8,284 10,868
Net income 1 2,166 4,758 3,008 5,522 4,352 4,667 6,539 8,323
Net margin 40.37% 47.06% 35.46% 37.83% 26.42% 23.57% 27.69% 29.4%
EPS 2 34.03 72.21 45.54 83.65 66.02 67.88 93.40 123.2
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,730 5,948 8,574
FCF margin 23.24% 60.59% 23.3% 24.63% 42.58% 13.79% 25.19% 30.29%
FCF Conversion (EBITDA) 44.9% 93.21% 60.5% 53.5% 124.89% 43.17% 71.59% 78.45%
FCF Conversion (Net income) 57.57% 128.75% 65.69% 65.1% 161.17% 58.5% 90.97% 103.02%
Dividend per Share 2 - - - - - - - -
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,343 3,553 2,310 2,619 2,119 3,162 5,281 4,087 5,227 2,854 4,198 7,052 4,744 4,678 4,143 4,990 9,039 5,285 5,538 5,229
EBITDA 1 4,583 1,345 905 1,016 529 1,263 1,792 1,953 2,974 458 1,520 1,978 1,739 1,899 823 1,508 2,412 1,712 2,045 2,850
EBIT 1 4,568 1,319 890 809 514 1,247 1,761 1,931 2,665 437 1,497 1,934 1,717 1,670 801 390 2,229 1,631 1,818 1,547
Operating Margin 72.02% 37.12% 38.53% 30.89% 24.26% 39.44% 33.35% 47.25% 50.99% 15.31% 35.66% 27.42% 36.19% 35.7% 19.33% 7.82% 24.66% 30.87% 32.84% 29.58%
Earnings before Tax (EBT) 1 4,682 1,846 1,171 966 612 2,489 3,101 3,272 662 286 1,723 2,009 2,702 926 1,716 198.5 3,374 1,713 1,687 1,634
Net income 1 3,647 1,402 890 716 465 1,891 2,356 2,582 584 226 1,357 1,583 2,129 640 1,325 463.2 2,598 1,371 1,273 1,280
Net margin 57.5% 39.46% 38.53% 27.34% 21.94% 59.8% 44.61% 63.18% 11.17% 7.92% 32.32% 22.45% 44.88% 13.68% 31.98% 9.28% 28.74% 25.95% 22.99% 24.47%
EPS 2 55.52 21.25 13.47 10.82 7.050 28.66 35.71 39.17 8.820 3.430 20.61 24.03 32.32 9.670 20.18 -2.076 39.51 19.53 18.52 14.88
Dividend per Share 2 - - - - - - - - - - - - - - - - - - - -
Announcement Date 12/08/20 11/08/21 10/11/21 16/02/22 11/05/22 10/08/22 10/08/22 09/11/22 22/02/23 10/05/23 03/08/23 03/08/23 07/11/23 14/02/24 02/05/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 10,790 16,079 19,338 22,324 28,135 25,884 32,206 38,868
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,730 5,948 8,574
ROE (net income / shareholders' equity) 19.6% 28.7% 14.6% 22.2% 14.8% 15.3% 16.2% 17.8%
ROA (Net income/ Total Assets) 18.4% 26.2% 13.1% 20.1% 13.3% 13.8% 13.9% 16.1%
Assets 1 11,803 18,143 22,885 27,453 32,704 33,736 46,931 51,593
Book Value Per Share 2 216.0 290.0 336.0 416.0 479.0 534.0 657.0 784.0
Cash Flow per Share 2 21.50 97.60 33.70 59.30 112.0 87.50 126.0 163.0
Capex 1 79 307 252 317 366 480 515 647
Capex / Sales 1.47% 3.04% 2.97% 2.17% 2.22% 2.42% 2.18% 2.29%
Announcement Date 19/02/20 23/02/21 16/02/22 22/02/23 14/02/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799 DKK
Average target price
2,464 DKK
Spread / Average Target
+36.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.80% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+22.24% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.35% 20.36B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.61% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.48% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.20% 13.59B
INSMED INCORPORATED Stock Insmed Incorporated
+121.67% 11.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GE91 Stock
  5. Financials Genmab A/S